ArticleMateria socio-medica2025
Duffy Antigen Receptor for Chemokines (DARC) Polymorphisms and Susceptibility to Plasmodium Vivax Malaria in Sudan: a Case - Control Study.
Article in Materia socio-medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuffy-negative individuals were long considered resistant to Plasmodium vivax, yet emerging infections challenge this assumption, underscoring the need to examine Duffy antigen receptor for chemokines (DARC) gene polymorphisms and clarify evolving susceptibility patterns.
objectiveThis study investigated the association between DARC genetic variants and susceptibility to P. vivax infection to elucidate transmission patterns and explain the rising incidence of P. vivax infection in Sudan.
methodsA total of 405 participants were recruited for the study, including 202 patients with a confirmed diagnosis of P. vivax malaria and 203 blood donors serving as the control group. DNA was extracted from the peripheral blood, and DARC polymorphic variants were analyzed using polymerase chain reaction- sequence specific primer (PCR-SSP).
resultsThe study showed that the Duffy-negative homozygous genotype FYBES/FYBES was present in both P. vivax-infected patients and the control group; however, it was significantly more frequent in healthy blood donors. The frequencies of the homozygous FYB/FYB genotype and the two heterozygous genotypes FYB/FYA and FYB/FYBES were substantially higher among the patients with P. vivax malaria than in the control group. The homozygous genotype FYA/FYA was more frequent among P. vivax malaria patients, while the heterozygous genotype FYA/FYBES was more common in the control group; however, the differences were not statistically significant. The FYAES allele was not detected in either group.
conclusionThere was a potential association between FYA and FYB alleles and susceptibility to P. vivax infection. The FYBES allele confers partial resistance to P. vivax malaria, as some infected individuals were found to carry the homozygous Duffy-negative genotype (FYBES/ FYBES).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.